SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing...
-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy -- Foundation Medicine, today...
Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning...
By Pietro Lombardi This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (June 20, 2018...
WeissLaw LLP: Foundation Medicine, Inc. Acquisition May Not Be In The Best Interest of FMI Shareholders PR Newswire NEW YORK, June 19, 2018 NEW YORK, June 19, 2018 /PRNewswire/ -- WeissLaw LLP is...
(Adds details on Roche's stake in FMI, background on FMI.) By Pietro Lombardi Roche Holding AG (ROG.EB) and Foundation Medicine Inc. (FMI) have reached a definitive merger agreement, under...
By Pietro Lombardi Roche Holding AG (ROG.EB) and Foundation Medicine Inc. (FMI) reached a definitive merger agreement Tuesday, under which Roche will acquire all the outstanding shares in...
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Goldman Sachs...
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated from its comprehensive genomic profiling (CGP) assays will be presented at the American Society of Clinical...
-- Pan-Cancer MSI Companion Diagnostic for KEYTRUDA® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.